Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate-loaded tumor cell-derived microparticles
- Development stage
- Unknown
- Lead developer
- Peking Union Medical College
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intrapleural
01
Overview
Methotrexate-loaded tumor cell-derived microparticles (MPs-MTX or TMPs-MTX) is an innovative drug delivery system and immunotherapeutic agent developed by Peking Union Medical College for the treatment of malignant pleural effusion (MPE). This therapy utilizes tumor-derived extracellular vesicles (microparticles) as natural carriers to encapsulate the chemotherapeutic agent methotrexate. Unlike traditional systemic chemotherapy, MPs-MTX is administered via intrapleural infusion and acts by mobilizing and activating neutrophils within the pleural space. These activated neutrophils then exert potent anti-tumor effects, making the drug an effective treatment for MPE secondary to advanced non-squamous non-small cell lung cancer or breast cancer. The microparticles serve a dual role as both a delivery vehicle for the cytotoxic payload and a biological stimulus for the local immune environment.
- Other names
- methotrexate-packaging tumor cell-derived microparticlestumor cell-derived microparticles packaging methotrexatemicroparticles packaging methotrexate
02
Targets
DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on methotrexate-loaded tumor cell-derived microparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate-loaded tumor cell-derived microparticles.